Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help stre | ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

This collaboration comes on the heels of Astellas Pharma's October 2023 memorandum of understanding with BioLabs Global and ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a ...

Astellas will “generally shift our resources to focus on slightly later-stage opportunities,” he explained. 2. Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma After reports ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions- TOKYO, March 5, 2025 /PRNewswire/ -- Astellas ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing. Astellas ...

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...